The accuracy of FibroScan, FIB-4, and nonalcoholic fatty liver disease fibrosis score in predicting biopsy-defined fibrosis and steatosis across all fibrosis stages in patients with metabolic dysfunction associated steatotic liver disease

The accuracy of FibroScan, FIB-4, and nonalcoholic fatty liver disease fibrosis score in predicting biopsy-defined fibrosis and steatosis across all fibrosis stages in patients with metabolic dysfunction associated steatotic liver disease. Thallapureddy K, Twitchell D, Ott K, Pedicone LD, Owo C, Kumar N, Gelfond...

Read More

MASH pubs highlight

Texas Liver Institute’s Dr. Eric Lawitz and colleagues publish clinical trial results on 2 exciting drugs in development for metabolic dysfunction-associated steatohepatitis (MASH) in the prestigious New England Journal of

Read More